Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

493800 PARP Inhibitor VI, NU1025 - CAS 90417-38-2 - Calbiochem

Overview

Replacement Information

Key Spec Table

CAS #Empirical Formula
90417-38-2C₉H₈N₂O₂

Products

Catalogue NumberPackaging Qty/Pack
493800-5MGCN Plastic ampoule 5 mg
Description
OverviewA potent inhibitor poly(ADP-ribose) polymerase (PARP; IC50 = 0.40 µM). Has been shown to potentiate the cytotoxicity of the DNA-methylating agent MTIC [5-(3-N-methyltriazen-1-yl)-imidazole-4-carboxamide] and ionizing irradiation in murine L210 leukemia cells.
Catalogue Number493800
Brand Family Calbiochem®
Synonyms8-Hydroxy-2-methylquinazoline-4-one
References
ReferencesDelaney, C.A., et al. 2000. Clin. Cancer Res. 6, 2860.
Boulton, S., et al. 1999. Carcinogenesis 20, 199.
Bowman, K.J., et al. 1998. Br. J. Cancer 78, 1269.
Griffin, R.J., et al. 1998. J. Med. Chem. 41, 5247.
Griffin, R.J., et al. 1996. Pharm. Sci. 2, 43.
Boulton, S., et al. 1995. Br. J. Cancer 72, 849.
Griffin, R.J., et al. 1995. Anticancer Drug Res. 10, 507.
Product Information
CAS number90417-38-2
ATP CompetitiveN
FormOff-white solid
Hill FormulaC₉H₈N₂O₂
Chemical formulaC₉H₈N₂O₂
ReversibleN
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary TargetPARP
Primary Target IC<sub>50</sub>0.4 µM against poly(ADP-ribose) polymerase (PARP)
Purity≥98% by HPLC
Physicochemical Information
Cell permeableN
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage -20°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
493800-5MGCN 04055977272826

Documentation

PARP Inhibitor VI, NU1025 - CAS 90417-38-2 - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

PARP Inhibitor VI, NU1025 - CAS 90417-38-2 - Calbiochem Certificates of Analysis

TitleLot Number
493800

References

Reference overview
Delaney, C.A., et al. 2000. Clin. Cancer Res. 6, 2860.
Boulton, S., et al. 1999. Carcinogenesis 20, 199.
Bowman, K.J., et al. 1998. Br. J. Cancer 78, 1269.
Griffin, R.J., et al. 1998. J. Med. Chem. 41, 5247.
Griffin, R.J., et al. 1996. Pharm. Sci. 2, 43.
Boulton, S., et al. 1995. Br. J. Cancer 72, 849.
Griffin, R.J., et al. 1995. Anticancer Drug Res. 10, 507.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision13-August-2008 RFH
Synonyms8-Hydroxy-2-methylquinazoline-4-one
DescriptionA potent poly(ADP-ribose) polymerase (PARP) inhibitor (IC50 = 400 nM) that potentiates the cytotoxicity of various DNA-active agents, including the DNA-methylating compound MTIC [5-(3-N-methyltriazen-1-yl)-imidazole-4-carboxamide], the DNA strand break-inducing drug temozolomide, topotecan, bleomycin, and ionizing radiation in murine L1210 leukemia cells, Chinese hamster ovary cells, and in a variety of human tumor cell lines.
FormOff-white solid
Intert gas (Yes/No) Packaged under inert gas
CAS number90417-38-2
Chemical formulaC₉H₈N₂O₂
Structure formulaStructure formula
Purity≥98% by HPLC
SolubilityDMSO (25 mg/ml). This solution can be further diluted 1:100 in tissue culture medium before use.
Storage Protect from light
-20°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Toxicity Standard Handling
ReferencesDelaney, C.A., et al. 2000. Clin. Cancer Res. 6, 2860.
Boulton, S., et al. 1999. Carcinogenesis 20, 199.
Bowman, K.J., et al. 1998. Br. J. Cancer 78, 1269.
Griffin, R.J., et al. 1998. J. Med. Chem. 41, 5247.
Griffin, R.J., et al. 1996. Pharm. Sci. 2, 43.
Boulton, S., et al. 1995. Br. J. Cancer 72, 849.
Griffin, R.J., et al. 1995. Anticancer Drug Res. 10, 507.